These results suggested that EGFR inhibition could effectively prevent the initial or early-phase pathological events involved in the development of MPGN and thus, may represent a potential therapeutic option in halting the progression of GN. The gene discussed is EGFR; the disease is primary membranoproliferative glomerulonephritis.